GCP
SPRY icon

GSA Capital Partners’s ARS Pharmaceuticals SPRY Stock Holding History

GSA Capital Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45,252
Closed -$790K – 2060
2025
Q2 		$790K Buy
45,252
+17,800
+65% +$257K 0.06% 617
2025
Q1 		$345K Buy
27,452
+9,878
+56% +$119K 0.03% 1047
2024
Q4 		$185K Sell
17,574
-81,326
-82% -$1.14M 0.01% 1432
2024
Q3 		$1.43M Buy
98,900
+39,921
+68% +$475K 0.11% 249
2024
Q2 		$502K Sell
58,979
-69,910
-54% -$620K 0.04% 963
2024
Q1 		$1.32M Buy
128,889
+13,545
+12% +$101K 0.1% 277
2023
Q4 		$632K Buy
+115,344
New +$505K 0.05% 639
2023
Q2 		– Sell
-10,744
Closed -$70K – 1918
2023
Q1 		$70K Buy
+10,744
New +$82.5K 0.01% 1385
2022
Q2 		– Sell
-22,894
Closed -$80K – 1773
2022
Q1 		$80K Buy
22,894
+11,303
+98% +$49.2K 0.01% 1316
2021
Q4 		$77K Buy
+11,591
New +$94.2K 0.01% 1331

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

GSA Capital Partners's SPRY Position: Q3 2025 in Review

GSA Capital Partners sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 45,252 shares — an estimated $790K sold.

GSA Capital Partners first reported a position in SPRY in Q4 2021 and held it in 10 quarters. The position peaked at $1.43M in Q3 2024. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • GSA Capital Partners reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 45,252 ARS Pharmaceuticals shares in Q3 2025, an estimated $790K.
  • GSA Capital Partners first reported a position in ARS Pharmaceuticals in Q4 2021 and held it in 10 quarters.
  • GSA Capital Partners's ARS Pharmaceuticals position peaked at $1.43M in Q3 2024.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.